American Association for Cancer Research
Browse

Supplementary Tables 1 - 2 from PME-1 Modulates Protein Phosphatase 2A Activity to Promote the Malignant Phenotype of Endometrial Cancer Cells

Download (340.28 kB)
journal contribution
posted on 2023-03-30, 22:03 authored by Ewa Wandzioch, Michelle Pusey, Amy Werda, Sophie Bail, Aishwarya Bhaskar, Mariya Nestor, Jing-Jing Yang, Lyndi M. Rice

PDF file - 340K, Table S1. siRNA and shRNA sequences targeting the gene PPME1, which codes for PME-1 protein. Table S2. Tumor and normal adjacent tissue (NAT) matched pairs were purchased from Proteogenex.

History

ARTICLE ABSTRACT

Protein phosphatase 2A (PP2A) negatively regulates tumorigenic signaling pathways, in part, by supporting the function of tumor suppressors like p53. The PP2A methylesterase PME-1 limits the activity of PP2A by demethylating its catalytic subunit. Here, we report the finding that PME-1 overexpression correlates with increased cell proliferation and invasive phenotypes in endometrial adenocarcinoma cells, where it helps maintain activated ERK and Akt by inhibiting PP2A. We obtained evidence that PME-1 could bind and regulate protein phosphatase 4 (PP4), a tumor-promoting protein, but not the related protein phosphatase 6 (PP6). When the PP2A, PP4, or PP6 catalytic subunits were overexpressed, inhibiting PME-1 was sufficient to limit cell proliferation. In clinical specimens of endometrial adenocarcinoma, PME-1 levels were increased and we found that PME-1 overexpression was sufficient to drive tumor growth in a xenograft model of the disease. Our findings identify PME-1 as a modifier of malignant development and suggest its candidacy as a diagnostic marker and as a therapeutic target in endometrial cancer. Cancer Res; 74(16); 4295–305. ©2014 AACR.